DePuy Synthes recently released the report, “Improving the Value of Primary Total Knee Arthroplasty: the ATTUNE® Knee System,” that analyses the ATTUNE Knee’s current clinical and economic data.
The report concludes that in a value-based healthcare environment with cost constraints and growing procedure volumes, the value of a knee replacement implant is measured not only by how long the implant lasts (implant survivorship), but also through patient reported outcomes and the economic benefits of the procedure.
The report, which was released during the European Knee Society Arthroplasty Conference in London, was commissioned by DePuy Synthes and is authored by David Fisher, Director of the Total Joint Center of Excellence at OrthoIndy Hospital in Indianapolis, Indiana, and Professor David Parkin, an Honorary Visiting Professor at City, University of London and a Senior Visiting Fellow, Office of Health Economics.
The report analyses approaches for evaluating primary total knee arthroplasty (TKA) from a clinical and health economic perspective, and assesses the current data from DePuy Synthes’ ATTUNE Knee Evidence Generation Program. This program, the largest of its kind in DePuy Synthes’ history, includes a wide range of data from company-initiated studies, investigator-initiated studies, independent studies and national joint registries.
In their analysis, Fisher and Parkin conclude that, “Based on available data, the ATTUNE Knee appears to be advancing outcomes for patients and creating value for clinicians, providers and payors in a challenging and dynamic healthcare environment.”
This report comes at a time when the entire episode of patient care is a major focus for global healthcare providers, placing a laser-like focus on both improving patient outcomes and managing costs. The introduction of the Hospital Structure Act in Germany and the Payments by Results system in England are two examples of the drive to minimise the total cost of care while maintaining quality. Against this backdrop, data from a comprehensive evidence-generation program could help provide evidence to support decisions about a device’s overall value.
“The success of any knee replacement is multifactorial, and the data on the ATTUNE Knee gives me confidence that I’m using a knee replacement that is delivering value for patients and the healthcare system,” said Dr. Fisher.
Added Professor Parkin: “Quality of life, as measured by patient reported outcomes, has been shown to be a driver of cost effectiveness in knee replacement. The evidence that I’ve seen about the effectiveness of the ATTUNE Knee in improving patient reported outcomes suggests it could deliver a better quality of life for patients compared to some other leading knee systems. Therefore, the ATTUNE Knee may potentially play a role in helping reduce some of the healthcare and societal costs associated with knee osteoarthritis.”
To read the report, visit www.ProvingthePromise.com
